AbbVie

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility in Tuas Biomedical Park, adding 24,000 liters of biologics drug-substance capacity and over 100 jobs. The expansion is expected to become operational in 2026.

NEXGEL's subsidiary CG Converting and Packaging executed a supply agreement with AbbVie to supply gel pads for use with AbbVie's Rapid Acoustic Pulse device for cellulite treatment.

EQT Life Sciences announced that AbbVie and iSTAR Medical entered a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device. Deal terms include a $60 million upfront payment to iSTAR Medical.

AbbVie and iSTAR Medical announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device. The deal includes a $60 million upfront payment to iSTAR Medical, which will continue development and commercialization up to completion of the U.S. PMA study.

Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc., adding the RESONIC device for cellulite treatment to its body contouring portfolio.

AbbVie announced a $139 million (€113.6 million) expansion of its manufacturing facility in Ballytivnan, Sligo, Ireland, to support its oncology pipeline. The investment will create approximately 100 new jobs over three years.